水仙环素的抗肿瘤活性及机制研究进展

杨敏; 林琪琪; 刘丹丹; 周宏宇

doi:10.12259/j.issn.2095-610X.S20240222

水仙环素的抗肿瘤活性及机制研究进展

doi: 10.12259/j.issn.2095-610X.S20240222

杨敏¹,
林琪琪¹,
刘丹丹^{1, 2, ,},
周宏宇^{1, 2, ,}

1.
昆明医科大学药学院暨云南省天然药物药理重点实验室，云南昆明　650500
2.
昆明医科大学现代生物医药产业学院，云南昆明　650500

基金项目: 国家自然科学基金资助项目（21907044，82160697）；云南省基础研究计划面上项目（202101AT070155）；云南省科技厅-昆明医科大学联合专项基金资助项目（ 202101AY070001-011）; 云南省“兴滇英才支持计划”青年人才项目（YNWR-QNBJ-2018-380，YNWR-QNBJ-2020-276）

详细信息

作者简介:
杨敏（2001～），女，重庆大足人，在读2020级药学专业本科生

通讯作者:
刘丹丹，E-mail：liudandan@kmmu.edu.cn

周宏宇，E-mail：zhouhongyu@kmmu.edu.cn

中图分类号: R966
计量
- 文章访问数: 1039
- HTML全文浏览量: 534
- PDF下载量: 19
- 被引次数: 0
出版历程
- 收稿日期: 2023-05-05
- 网络出版日期: 2024-02-27
- 刊出日期: 2024-02-25

Research Progress on the Anti-tumor Activity and Mechanism of Narciclasine

Min YANG¹,
Qiqi LIN¹,
Dandan LIU^{1, 2
, ,},
Hongyu ZHOU^{1, 2
, ,}

1.
School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products，Kunming Medical University，Kunming Yunnan 650500
2.
College of Modern Biomedical Industry，Kunming Medical University，Kunming Yunnan 650500，China

摘要

摘要: 水仙环素（narciclasine，NCS）是从石蒜科水仙属植物水仙的鳞茎中提取出的水鬼蕉碱型生物碱，被证实对多种肿瘤细胞具有显著的抑制活性。NCS的抗肿瘤作用机制多样，通过不同途径产生抗肿瘤作用，适应了当前研发多靶点抗肿瘤药物的趋向。本文结合NCS抑制乳腺癌细胞、结肠癌细胞、胃癌细胞、黑色素瘤细胞、多形性胶质母细胞瘤细胞、口腔癌细胞和原发性渗出性淋巴瘤细胞的作用及分子机制，对NCS近年来的抗肿瘤活性及作用机制研究进行综述，旨在为将来NCS类抗肿瘤药物的研发与设计提供思路和借鉴。
- 水仙环素 /
- 水鬼蕉碱型生物碱 /
- 抗肿瘤活性 /
- 分子机制
Abstract: Narciclasine（NCS）, a hymenocallis littoralis alkaloid extracted from the bulbs of the genus Narcissus in the Lycoriaceae family, has been proven to have significant anti-tumor activity against a variety of tumor cells. The antitumor mechanisms of NCS are diverse and NCS exhibits antitumor effects through different pathways, which adapts to the current trend of developing multi-target anti-tumor drugs. This review introduces the research progress of the anti-tumor activity and mechanism of NCS in recent years based on the inhibitory effect of NCS on gastric cancer cells, oral cancer cells, polymorphous glioblastoma cells, colon cancer cells, breast cancer cells, melanoma cells and primary exudative lymphoma cells, aiming to provide ideas and references for the research and development, and design of NCS type anti-tumor drugs in the future.
- Narciclasine /
- Hymenocallis Littoralis Alkaloids /
- Antitumor Activity /
- Molecular Mechanism

HTML全文

图 1 水仙环素的化学结构^[4]

Figure 1. Chemical structure of NCS

下载: 全尺寸图片幻灯片

参考文献(52)

[1]	毕凯健. 水仙环素衍生物的设计、合成及抗肿瘤活性研究[D]. 上海: 第二军医大学, 2016.
[2]	Antoszczak M. A medicinal chemistry perspective on sali-nomycin as a potent anticancer and anti-CSCs agent[J]. Eur J Med Chem,2019,164:366-377. doi: 10.1016/j.ejmech.2018.12.057
[3]	Dagogo-Jack I,Shaw A T. Tumour heterogeneity and re-sistance to cancer therapies[J]. Nat Rev Clin Oncol,2018,15(2):81-94. doi: 10.1038/nrclinonc.2017.166
[4]	Ingrassia L,Lefranc F,Dewelle J,et al. Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents[J]. J Med Chem,2009,52(4):1100-1114. doi: 10.1021/jm8013585
[5]	Ceriotti G. Narciclasine: An antimitotic substance from Narcissus bulbs[J]. Nature,1967,21(5076):595-596.
[6]	Fürst R. Narciclasine - an amaryllidaceae alkaloid with potent antitumor and anti-inflammatory properties[J]. Planta Med,2016,82(16):1389-1394. doi: 10.1055/s-0042-115034
[7]	Rárová L,Ncube B,Van Staden J,et al. Identification of Narciclasine as an in vitro anti-inflammatory component of Cyrtanthus contractus by correlation-based metabolomics[J]. Nat Prod,2019,82(5):1372-1376. doi: 10.1021/acs.jnatprod.8b00973
[8]	Bräutigam J,Bischoff I,Schürmann C,et al. Narciclasine inhibits angiogenic processes by activation of rho kinase and by downregulation of the VEGF receptor 2[J]. Mol Cell Cardiol,2019,135:97-108. doi: 10.1016/j.yjmcc.2019.08.001
[9]	De Castro Barbosa E,Alves T M A,Kohlhoff M,et al. Searching for plant-derived antivirals against dengue virus and Zika virus[J]. Virol J,2022,19(1):31.
[10]	Dumont P,Ingrassia L,Rouzeau S,et al. The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts[J]. Neoplasia,2007,9(9):766-776. doi: 10.1593/neo.07535
[11]	Min B S,Cao J J,Nakamura N,et al. Cytotoxic alkaloids and a Fla Villi from the bulbs of Crinum asiaticum var japonicum[J]. Chem Plmrm Bull,2001,49(9):1217-1219. doi: 10.1248/cpb.49.1217
[12]	Van Goietsenoven G,Mathieu V,Lefranc F,et al. Narciclasine as well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against brain cancers[J]. Med Res Rev,2013,33(2):439-455.
[13]	Qiu Y,Fang B,Thuy N T T,et al. Narciclasine suppresses esophageal cancer cell proliferation and migration by inhibiting the FAK signaling pathway[J]. Eur J Pharmacol,2022,921:174669.
[14]	马楠楠,陈宁,季宇彬,等. 水鬼蕉生物碱抗肿瘤研究进展[J]. 黑龙江医药,2013,26(2):205-208. doi: 10.3969/j.issn.1006-2882.2013.02.017
[15]	Kornienko A,Evidente A. Chemistry,biology,and medicinal potential of NCS and its congeners[J]. Chem Rev,2008,108(6):1982-2014. doi: 10.1021/cr078198u
[16]	Cao C,Huang W,Zhang N,et al. NCS induces autophagy-dependent apoptosis in triple-negative breast cancer cells by regulating the AMPK-ULK1 axis[J]. Cell Prolif,2018,51(6):12518. doi: 10.1111/cpr.12518
[17]	Beebe J D,Li J Y,Zhang J T. Two decades of research in discovery of anticancer drugs targeting STAT3,how close are we?[J]. Pharmacol Ther,2018,191:74-91. doi: 10.1016/j.pharmthera.2018.06.006
[18]	Mohan C D,Rangappa S,Preetham H D,et al. Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature[J]. Cancer Biol,2022,80:157-182. doi: 10.1016/j.semcancer.2020.03.016
[19]	Lv C,Huang Y,Huang R,et al. Narciclasine targets STAT3 via distinct mechanisms in tamoxifen-resistant breast cancer cells[J]. Mol Ther Oncolytics,2022,24:340-354. doi: 10.1016/j.omto.2021.12.025
[20]	Wang M,Liang L,Wang R,et al. Narciclasine,a novel topoisomerase I inhibitor,exhibited potent anti-cancer activity against cancer cells[J]. Nat Prod Bioprospect,2023,13(1):27. doi: 10.1007/s13659-023-00392-1
[21]	Liu L F,Wang J C. Supercoiling of the DNA template during transcription[J]. Proc Natl AcadSci USA,1987,84(20):7024-7027. doi: 10.1073/pnas.84.20.7024
[22]	Lichota A,Gwozdzinski K. Anticancer Activity of Natural Compounds from Plant and Marine Environment[J]. Int J Mol Sci,2018,19(11):3533. doi: 10.3390/ijms19113533
[23]	Pommiier Y,Pourquier P,Urasaki Y,et al. Topoisomerase 1 inhibitors: selectivity andcellular resistance[J]. Drug Resist Updat,1999,2(5):307-318. doi: 10.1054/drup.1999.0102
[24]	Said A H,Raufman J P,Xie G. The role of matrix metalloproteinases in colorectal cancer[J]. Cancers,2014,6:366-375. doi: 10.3390/cancers6010366
[25]	Pezeshkian Z,Nobili S,Peyravian N,et al. Insights into the Role of Matrix Metalloproteinases in Precancerous Conditions and in Colorectal Cancer[J]. Cancers,2021,13(24):6226. doi: 10.3390/cancers13246226
[26]	Ara ú jo R F,Jr,Lira G A,et al. Prognostic and diagnostic implications of MMP-2,MMP-9,and VEGF-α expressions in colorectal cancer[J]. Pathol Res Pract,2015,211(1):71-77. doi: 10.1016/j.prp.2014.09.007
[27]	Wang K,Zheng J,Yu J,et al. Knockdown of MMP-1 inhibits the progression of colorectal cancer by suppressing the PI3K/Akt/c-myc signaling pathway and EMT[J]. Oncol Rep,2020,43(4):1103-1112.
[28]	Mathieu V,Laguera B,Masi M,et al. Amaryllidaceae alkaloids decrease the proliferation,invasion,and secretion of clinically relevant cytokines by cultured human colon cancer cells[J]. Biomolecules,2022,12(9):1267. doi: 10.3390/biom12091267
[29]	Bie Y, Ge W, Yang Z, et al. The crucial role of CXCL8 and its receptors in colorectal liver metastasis[J]. Dis Markers, 2019, 2019: 8023460.
[30]	Wang Y,Wang K,Han GC,et al. Neutrophil infiltration favors colitis-associated tumorigenesis by activating the interleukin-1 (IL-1)/IL-6 axis[J]. Mucosal Immunol,2014,7(5):1106-1115. doi: 10.1038/mi.2013.126
[31]	Lin Y,He Z,Ye J,et al. Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer[J]. Onco Targets Ther,2020,13:13023-13032. doi: 10.2147/OTT.S278013
[32]	Yuan Y,He X,Li X,et al. NCS induces autophagy-mediated apoptosis in gastric cancer cells through the Akt/mTOR signaling pathway[J]. BMC Pharmacol Toxicol,2021,22(1):70. doi: 10.1186/s40360-021-00537-3
[33]	White E,Mehnert J M,Chan C S. Autophagy,metabolism,and Cancer[J]. Clin Cancer Res,2015,21:5037-5046. doi: 10.1158/1078-0432.CCR-15-0490
[34]	Deng S,Shanmugam M K,Kumar A P,et al. Targeting autophagy using natural compounds for cancer prevention and therapy[J]. Cancer,2019,125(8):1228-1246. doi: 10.1002/cncr.31978
[35]	Marino G, Niso-Santano M, Baehrecke E H, et al Self-consumption: the interplay of autophagy and apoptosis[J]. Nat Rev Mol Cell Biol, 2014, 15（2）: 81–94.
[36]	Moosavi M A,Haghi A,Rahmati M,et al. Phytochemicals as potent modulators of autophagy for cancer therapy[J]. Cancer Lett,2018,424:46-69. doi: 10.1016/j.canlet.2018.02.030
[37]	Liu R,Li J,Zhang T,et al. Itraconazole suppresses the growth of glioblastoma through induction of autophagy: involvement of abnormal cholesterol trafficking[J]. Autophagy,2014,10(7):1241-1255. doi: 10.4161/auto.28912
[38]	Elgendy M,Sheridan C,Brumatti G,et al. Oncogenic ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival[J]. Mol Cell,2011,42(1):23-35. doi: 10.1016/j.molcel.2011.02.009
[39]	He C,Klionsky D J. Regulation mechanisms and signaling pathways of autophagy[J]. Annu Rev Genet,2009,43:67-93. doi: 10.1146/annurev-genet-102808-114910
[40]	Jung C H,Ro S H,Cao J,et al. mTOR regulation of autophagy[J]. FEBS Lett,2010,584(7):1287-1295. doi: 10.1016/j.febslet.2010.01.017
[41]	Van Goietsenoven G,Hutton J,Becker J P,et al. Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas[J]. FASEB J,2010,24(11):4575-4584. doi: 10.1096/fj.10-162263
[42]	Lefranc F,Sauvage S,Van Goietsenoven G,et al. NCS,a plant growth modulator,activates Rho and stress fibers in glioblastoma cells[J]. Mol Cancer Ther,2009,8(7):1739-1750. doi: 10.1158/1535-7163.MCT-08-0932
[43]	Scott R W,Olson M. LIM kinases: function,regulation and association with human disease[J]. J Mol Med,2007,85(6):555-568. doi: 10.1007/s00109-007-0165-6
[44]	Arber S,Barbayannis F A,Hanser H,et al. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase[J]. Nature,1998,393(6687):805-809. doi: 10.1038/31729
[45]	Le Mercier M,Mathieu V,Haibe-Kains B,et al. Knocking down galectin-1 in human Hs683 glioblastoma cells impairs both angiogenesis through ORP150 depletion and endoplasmic reticulum stress responses[J]. J Neuropathol Exp Neurol,2008,67(5):456-469. doi: 10.1097/NEN.0b013e318170f892
[46]	Raftopoulou M,Hall A. Cell migration: Rho GTPases lead the way[J]. Dev Biol,2004,265(1):23-32. doi: 10.1016/j.ydbio.2003.06.003
[47]	Tabu K,Ohba Y,Suzuki T,et al. Oligodendrocyte lineage transcription factor 2 inhibits the motility of a human glial tumor cell line by activating RhoA[J]. Mol Cancer Res,2007,5(10):1099-1109. doi: 10.1158/1541-7786.MCR-07-0096
[48]	Shieu M K,Ho H Y,Lin C C,et al. NCS suppresses oral cancer metastasis by modulating cathepsin B and extracellular signal-related kinase pathways[J]. Biomed Pharmacother,2023,158:114159. doi: 10.1016/j.biopha.2022.114159
[49]	Q Peng,Deng Z,Pan H,et al. Mitogen-activated protein kinase signaling pathway in oral cancer[J]. Oncol Lett,2018,15(2):1379-1388.
[50]	Gopalakrishnan R,Matta H,Choi S,et al. NCS,an isocarbostyril alkaloid,has preferential activity against primary effusion lymphoma[J]. Sci Rep,2020,10(1):5712. doi: 10.1038/s41598-020-62690-9
[51]	Meyer N,Penn L Z. Refecting on 25 years with MYC[J]. Nat Rev Cance,2008,8(12):976-990. doi: 10.1038/nrc2231
[52]	Tolani B,Gopalakrishnan R,Punj V,et al. Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors[J]. Oncogene,2014,33(22):2928-2937. doi: 10.1038/onc.2013.242

计量

文章访问数: 1039
HTML全文浏览量: 534
PDF下载量: 19
被引次数: 0

姓名
邮箱
手机号码
标题
留言内容
验证码

留言板

水仙环素的抗肿瘤活性及机制研究进展

doi: 10.12259/j.issn.2095-610X.S20240222

作者简介:
杨敏（2001～），女，重庆大足人，在读2020级药学专业本科生

通讯作者:
刘丹丹，E-mail：liudandan@kmmu.edu.cn

周宏宇，E-mail：zhouhongyu@kmmu.edu.cn

计量

Research Progress on the Anti-tumor Activity and Mechanism of Narciclasine

计量

目录

[1]	李力, 张瑞仙. 环状RNA在系统性红斑狼疮中的潜在应用研究进展, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20240622
[2]	徐云容, 唐梓闻, 何飞. 骨修复材料促成骨作用的分子机制, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231007
[3]	吴华杰, 屠德桢, 李磊, 乔涵, 李国萍. 白藜芦醇对鼻咽癌转移能力的影响及其分子机制, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20230220
[4]	黄云, 赵安楠, 刘秋月, 高伟民, 李霁. 基于响应面法优化水鬼蕉中水仙环素的提取工艺, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20231104
[5]	张莉, 王雨婷, 石佳宁, 余丹, 杨仁华, 沈志强, 龙江, 陈鹏. 基于网络药理学分析灯盏乙素治疗动脉粥样硬化的分子机制和体内验证, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220804
[6]	秦杰琛, 左笑菲, 邹澄, 庹呈杰, 张科涛, 张晓梅, 赵庆. 结构改造制备抗菌和抗肿瘤的姜科二萜衍生物, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210501
[7]	秦杰琛, 曾小娟, 张韶湘, 张晓梅, 刘鑫洋, 邹澄, 赵庆. 氰基硼氢化钠还原胺化京尼平合成拟生物碱与活性, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20210216
[8]	连文静, 贺小琼, 赵庆, 王宜挺, 吴怡, 尤雨桐. 松萝烟酰胺的合成及抗肿瘤活性研究, 昆明医科大学学报.
[9]	李生浩, 李俊义, 武昆利, 徐晶晶, 常国楫, 王卫群, 张燕玲, 马志强, 王文林, 李树德. 龙胆苦苷的药理作用及分子机制研究进展, 昆明医科大学学报.
[10]	周金娜, 董成梅, 邹澄, 秦杰琛, 赵庆, 胡建林, 段文越, 杨为民. 酸酐酯化法制备原人参二醇衍生物及其抗肿瘤活性, 昆明医科大学学报.
[11]	刘军慧, 钟飞, 韩少玲, 邹蕾. 秋水仙碱、苯溴马隆胶囊联合治疗痛风性关节炎非急性发作期, 昆明医科大学学报.
[12]	李瑞, 段文越, 邹澄, 赵庆, 黄丽, 周金娜, 胡建林, 杨为民. 一个新颖的三七皂苷元衍生物及其抗肿瘤活性, 昆明医科大学学报.
[13]	陈鹏, 阳锡军, 李春满, 刘锋, 阿永俊. 槲皮素对裸鼠肝癌切除术后肿瘤复发的影响及机制, 昆明医科大学学报.
[14]	姜重阳, 贺小琼, 姚乾, 税靖霖. 地衣活性化合物C11H12O5体外抗肿瘤作用, 昆明医科大学学报.
[15]	海青山, 马晓霞, 杨榆青, 杨竹雅. 滇西乌头中三种二萜生物碱相关药效和毒性的对比, 昆明医科大学学报.
[16]	李瑞, 陈晨, 邹澄, 赵庆, 郭巍怡, 黄丽, 杜如男, 杨为民. 一个新颖的人参皂苷元衍生物及其抗肿瘤活性（英文）, 昆明医科大学学报.
[17]	李继印. 液相色谱-质谱法测定云南草乌中双酯型生物碱的含量, 昆明医科大学学报.
[18]	孙惠峰. 青刺果总生物碱抗菌活性研究, 昆明医科大学学报.
[19]	李勇. 阿坝当归的化学成分及体外抗肿瘤活性研究, 昆明医科大学学报.
[20]	李勇. 滇产隆萼当归化学成分体外抗肿瘤活性研究, 昆明医科大学学报.

留言板

水仙环素的抗肿瘤活性及机制研究进展

doi: 10.12259/j.issn.2095-610X.S20240222

作者简介: 杨敏（2001～），女，重庆大足人，在读2020级药学专业本科生

通讯作者: 刘丹丹，E-mail：liudandan@kmmu.edu.cn 周宏宇，E-mail：zhouhongyu@kmmu.edu.cn

计量

出版历程

Research Progress on the Anti-tumor Activity and Mechanism of Narciclasine

计量

出版历程

目录

作者简介:
杨敏（2001～），女，重庆大足人，在读2020级药学专业本科生

通讯作者:
刘丹丹，E-mail：liudandan@kmmu.edu.cn

周宏宇，E-mail：zhouhongyu@kmmu.edu.cn